Articles
8 June 2009
Vol. 2 No. 3: Cervo Preclinical Working Conference, Cervo Ligure, October 6-8, 2005
https://doi.org/10.4081/hmr.v2i3.365

Use of cDNA microarrays to estimate gene modulation profiles induced by zoledronic acid treatment in androgen-resistant prostate cancer cell line (PC3)

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
163
Views
154
Downloads

Authors

Dr. Santini
support@pagepress.org
B Vincenzi
M Rosolowski
L Altucci
M Campioni
M Loeffler
A Baldi
G Tonini
The LNCaP and the PC3 cells are widely used as models for prostate cancer. Aminobisphosphonates have clearly demonstrated to inhibit proliferation and induce apoptosis in these cells by interfering with the mevalonate pathway. The types and pattern of downstream genes modulated by zoledronic acid (ZA) treatment are unknown. We used a cDNA microarray platform to analyse the genetic modulation induced by ZA in the PC3 prostate cancer cell line.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Use of cDNA microarrays to estimate gene modulation profiles induced by zoledronic acid treatment in androgen-resistant prostate cancer cell line (PC3). (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(3). https://doi.org/10.4081/hmr.v2i3.365